HRP20220414T1 - Inhibitori lizin specifične demetilaze-1 - Google Patents
Inhibitori lizin specifične demetilaze-1 Download PDFInfo
- Publication number
- HRP20220414T1 HRP20220414T1 HRP20220414TT HRP20220414T HRP20220414T1 HR P20220414 T1 HRP20220414 T1 HR P20220414T1 HR P20220414T T HRP20220414T T HR P20220414TT HR P20220414 T HRP20220414 T HR P20220414T HR P20220414 T1 HRP20220414 T1 HR P20220414T1
- Authority
- HR
- Croatia
- Prior art keywords
- optionally substituted
- compound
- pharmaceutically acceptable
- acceptable salt
- group
- Prior art date
Links
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title claims 3
- 239000004472 Lysine Substances 0.000 title claims 3
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 16
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 150000002431 hydrogen Chemical group 0.000 claims 3
- -1 substituted Chemical class 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 claims 2
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- XKUQXIITJZVRCO-UHFFFAOYSA-N 4-[1-(4-cyclopropylphenyl)-4-(2,8-diazaspiro[4.5]decan-8-yl)-6-oxopyrimidin-2-yl]-2-fluorobenzonitrile Chemical compound C1(CC1)C1=CC=C(C=C1)N1C(=NC(=CC1=O)N1CCC2(CCNC2)CC1)C1=CC(=C(C#N)C=C1)F XKUQXIITJZVRCO-UHFFFAOYSA-N 0.000 claims 1
- UFXSIXUFBVKJOV-UHFFFAOYSA-N 4-[4-(1,2,3,3a,4,6,7,7a-octahydropyrrolo[3,2-c]pyridin-5-yl)-1-(4-cyclopropylphenyl)-6-oxopyrimidin-2-yl]-2-fluorobenzonitrile Chemical compound N1CCC2CN(CCC21)C=1N=C(N(C(C=1)=O)C1=CC=C(C=C1)C1CC1)C1=CC(=C(C#N)C=C1)F UFXSIXUFBVKJOV-UHFFFAOYSA-N 0.000 claims 1
- VOLKYVYXKVIHMQ-UHFFFAOYSA-N 4-[4-(1,2,3,3a,4,6,7,7a-octahydropyrrolo[3,4-c]pyridin-5-yl)-1-(4-cyclopropylphenyl)-6-oxopyrimidin-2-yl]-2-fluorobenzonitrile Chemical compound C1NCC2CN(CCC21)C=1N=C(N(C(C=1)=O)C1=CC=C(C=C1)C1CC1)C1=CC(=C(C#N)C=C1)F VOLKYVYXKVIHMQ-UHFFFAOYSA-N 0.000 claims 1
- PDSZKPHSJJBAKV-UHFFFAOYSA-N 4-[4-(4-aminopiperidin-1-yl)-1-(2-methylindazol-5-yl)-6-oxopyrimidin-2-yl]-2-fluorobenzonitrile Chemical compound NC1CCN(CC1)C=1N=C(N(C(C=1)=O)C1=CC2=CN(N=C2C=C1)C)C1=CC(=C(C#N)C=C1)F PDSZKPHSJJBAKV-UHFFFAOYSA-N 0.000 claims 1
- FDZCHVVKXRRHPO-UHFFFAOYSA-N 4-[4-(4-aminopiperidin-1-yl)-1-(3-fluoro-4-methoxyphenyl)-6-oxopyrimidin-2-yl]-2-fluorobenzonitrile Chemical compound NC1CCN(CC1)C=1N=C(N(C(C=1)=O)C1=CC(=C(C=C1)OC)F)C1=CC(=C(C#N)C=C1)F FDZCHVVKXRRHPO-UHFFFAOYSA-N 0.000 claims 1
- FLOKQIAPBONYCU-UHFFFAOYSA-N 4-[4-(4-aminopiperidin-1-yl)-1-(4-cyclopropyl-3-fluorophenyl)-6-oxopyrimidin-2-yl]-2-fluorobenzonitrile Chemical compound NC1CCN(CC1)C=1N=C(N(C(C=1)=O)C1=CC(=C(C=C1)C1CC1)F)C1=CC(=C(C#N)C=C1)F FLOKQIAPBONYCU-UHFFFAOYSA-N 0.000 claims 1
- AVUVQRVAPHIXNE-UHFFFAOYSA-N 4-[4-(4-aminopiperidin-1-yl)-1-(4-cyclopropylphenyl)-6-oxopyrimidin-2-yl]-2-fluorobenzonitrile Chemical compound NC1CCN(CC1)C=1N=C(N(C(C=1)=O)C1=CC=C(C=C1)C1CC1)C1=CC(=C(C#N)C=C1)F AVUVQRVAPHIXNE-UHFFFAOYSA-N 0.000 claims 1
- CCPUYJRNWGQHJA-UHFFFAOYSA-N 4-[4-(4-aminopiperidin-1-yl)-1-(4-methoxyphenyl)-6-oxopyrimidin-2-yl]-2-fluorobenzonitrile Chemical compound NC1CCN(CC1)C=1N=C(N(C(C=1)=O)C1=CC=C(C=C1)OC)C1=CC(=C(C#N)C=C1)F CCPUYJRNWGQHJA-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000005438 isoindazolyl group Chemical group 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- LWMPFIOTEAXAGV-UHFFFAOYSA-N piperidin-1-amine Chemical class NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 claims 1
- 150000003053 piperidines Chemical class 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Polyamides (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462020886P | 2014-07-03 | 2014-07-03 | |
| EP15814038.4A EP3164380B1 (en) | 2014-07-03 | 2015-06-29 | Inhibitors of lysine specific demethylase-1 |
| PCT/US2015/038345 WO2016003917A1 (en) | 2014-07-03 | 2015-06-29 | Inhibitors of lysine specific demethylase-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220414T1 true HRP20220414T1 (hr) | 2022-05-27 |
Family
ID=55019883
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220414TT HRP20220414T1 (hr) | 2014-07-03 | 2015-06-29 | Inhibitori lizin specifične demetilaze-1 |
| HRP20230595TT HRP20230595T1 (hr) | 2014-07-03 | 2015-06-29 | Inhibitori lizina specifične demetilaze-1 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230595TT HRP20230595T1 (hr) | 2014-07-03 | 2015-06-29 | Inhibitori lizina specifične demetilaze-1 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US9902719B2 (enExample) |
| EP (2) | EP3511319B1 (enExample) |
| JP (2) | JP6663866B2 (enExample) |
| KR (1) | KR102475498B1 (enExample) |
| CN (2) | CN106795103B (enExample) |
| AU (1) | AU2015284383B2 (enExample) |
| BR (1) | BR112017000043A2 (enExample) |
| CA (1) | CA2954049A1 (enExample) |
| CL (1) | CL2016003422A1 (enExample) |
| CO (1) | CO2017000549A2 (enExample) |
| CY (1) | CY1125127T1 (enExample) |
| DK (2) | DK3164380T3 (enExample) |
| EA (2) | EA033698B1 (enExample) |
| EC (1) | ECSP17006821A (enExample) |
| ES (2) | ES2907676T3 (enExample) |
| FI (1) | FI3511319T3 (enExample) |
| HR (2) | HRP20220414T1 (enExample) |
| HU (2) | HUE062558T2 (enExample) |
| IL (2) | IL249881B (enExample) |
| LT (2) | LT3511319T (enExample) |
| MX (2) | MX395534B (enExample) |
| PL (2) | PL3511319T3 (enExample) |
| PT (2) | PT3164380T (enExample) |
| RS (2) | RS64423B1 (enExample) |
| SA (1) | SA517380651B1 (enExample) |
| SG (2) | SG11201610975RA (enExample) |
| SI (2) | SI3164380T1 (enExample) |
| SM (2) | SMT202200136T1 (enExample) |
| WO (1) | WO2016003917A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6855466B2 (ja) | 2015-06-12 | 2021-04-07 | オリゾン ジェノミックス ソシエダッド アノニマ | Ｌｓｄ１阻害剤に関連するバイオマーカーおよびそれらの使用 |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| SG10201913331VA (en) | 2016-03-15 | 2020-03-30 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
| ES3042059T3 (en) | 2016-03-16 | 2025-11-18 | Oryzon Genomics Sa | Methods to determine kdm1a target engagement and chemoprobes useful therefor |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| EP3535420A1 (en) | 2016-11-03 | 2019-09-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| CN110996949A (zh) | 2017-08-03 | 2020-04-10 | 奥瑞泽恩基因组学股份有限公司 | 用于治疗行为改变的方法 |
| EP3833670B1 (en) * | 2018-08-10 | 2024-04-17 | Navire Pharma, Inc. | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer |
| CA3127993A1 (en) * | 2019-02-01 | 2020-08-06 | Hanmi Pharm. Co., Ltd. | Imidazopyridine derivative compounds and use of same |
| JP7532386B2 (ja) | 2019-02-01 | 2024-08-13 | ハンミ ファーマシューティカルズ カンパニー リミテッド | イミダゾピリジン誘導体化合物及びその用途 |
| CA3130638A1 (en) | 2019-03-20 | 2020-09-24 | Oryzon Genomics, S.A. | Methods of treating borderline personality disorder |
| CN120837494A (zh) | 2019-03-20 | 2025-10-28 | 奥莱松基因组股份有限公司 | 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法 |
| EP3994280A1 (en) | 2019-07-05 | 2022-05-11 | Oryzon Genomics, S.A. | Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors |
| US11360505B2 (en) | 2020-02-11 | 2022-06-14 | Simmonds Precision Products, Inc. | Distributed network time synchronization |
| CN114105950B (zh) * | 2020-08-31 | 2022-09-06 | 南京明德新药研发有限公司 | 吡唑类化合物及其应用 |
| TWI834127B (zh) * | 2021-03-11 | 2024-03-01 | 大陸商南京明德新藥研發有限公司 | 噻吩類化合物及其應用 |
| US20240216357A1 (en) * | 2021-03-24 | 2024-07-04 | Sichuan Huiyu Pharmaceutical Co., Ltd. | Polycyclic compound and application thereof |
| KR20230167102A (ko) | 2021-04-08 | 2023-12-07 | 오리존 지노믹스 에스.에이. | 골수성 암 치료를 위한 lsd1 억제제의 조합물 |
| CN116102533A (zh) * | 2021-11-11 | 2023-05-12 | 中国科学院上海药物研究所 | 一种芳杂环类化合物及其应用 |
| JP2025516647A (ja) | 2022-05-09 | 2025-05-30 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｌｓｄ１阻害薬を用いる悪性末梢神経鞘腫（ｍｐｎｓｔ）の治療法 |
| WO2023217784A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1963188A1 (de) * | 1969-12-17 | 1971-06-24 | Bayer Ag | Neue Cyanphenyl-1,4-dihydropyridinderivate |
| WO2002026718A2 (en) * | 2000-09-29 | 2002-04-04 | Millennium Pharmaceutical, Inc. | Bicyclic pyrimidin-4-one based inhibitors of factor xa |
| US7365069B2 (en) * | 2002-04-10 | 2008-04-29 | Bexel Pharmaceuticals Inc. | Pyrimidone derivatives |
| JP2005170792A (ja) * | 2002-11-22 | 2005-06-30 | Mitsubishi Pharma Corp | Ｌ−プロリン誘導体およびその医薬としての用途。 |
| EP1695969A4 (en) * | 2003-12-11 | 2008-11-26 | Mitsubishi Tanabe Pharma Corp | ALPHA-AMINO-ACID DERIVATIVES AND THEIR USE AS MEDICINE |
| WO2006073167A1 (ja) * | 2005-01-07 | 2006-07-13 | Ono Pharmaceutical Co., Ltd. | ピロリジン誘導体 |
| PL372332A1 (pl) * | 2005-01-19 | 2006-07-24 | ADAMED Sp.z o.o. | Nowe związki, pochodne kwasu 3-fenylopropionowego |
| WO2006129181A2 (en) * | 2005-06-03 | 2006-12-07 | Orchid Research Laboratories Limited | Preparation of 4-pyrimidone derivatives for treating inflammatory diseases |
| ES2397400T3 (es) * | 2005-09-01 | 2013-03-06 | Eli Lilly & Company | 6-arilalquilamino-2,3,4,5-tetrahidro-1H-benzo[D]azepinas como agonistas del receptor 5-HT2C |
| JP2007197324A (ja) * | 2006-01-23 | 2007-08-09 | Toray Ind Inc | ２，４，５−置換−１，３−アゾール誘導体 |
| TW200815428A (en) * | 2006-08-15 | 2008-04-01 | Wyeth Corp | Oxazolidone derivatives as PR modulators |
| US7652018B2 (en) | 2006-08-15 | 2010-01-26 | Wyeth Llc | Imidazolidin-2-one derivatives useful as PR modulators |
| PE20081803A1 (es) | 2007-03-09 | 2008-12-11 | Wyeth Corp | Sintesis y caracterizacion de la forma ii polimorfica de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)tiazol-4-il)benzonitrilo |
| CL2008002793A1 (es) * | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
| WO2009132310A1 (en) * | 2008-04-25 | 2009-10-29 | Wisconsin Alumni Research Foundation | Inhibitors of udp-galactopyranose mutase thwart mycobacterial growth |
| WO2011130515A1 (en) | 2010-04-14 | 2011-10-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production |
| WO2012009475A1 (en) * | 2010-07-14 | 2012-01-19 | Oregon Health & Science University | Methods of treating cancer with inhibition of lysine-specific demethylase 1 |
| US9388196B2 (en) * | 2012-03-06 | 2016-07-12 | Lupin Limited | Thiazole derivatives as alpha 7 nAChR modulators |
| SI3080100T1 (sl) * | 2013-12-11 | 2023-04-28 | Celgene Quanticel Research, Inc. | Inhibitorji lizin specifične demetilaze-1 |
| RU2016136091A (ru) * | 2014-02-14 | 2018-03-19 | Дзе Юниверсити Оф Бритиш Коламбиа | Соединения, воздействующие на днк-связывающий домен (dbd) андрогенового рецептора человека, в качестве терапевтических средств, а также способы их применения |
| WO2015168466A1 (en) * | 2014-05-01 | 2015-11-05 | Quanticel Pharmaceuticals, Inc. | Inhibitors of lysine specific demethylase-1 |
| FR3020945B1 (fr) | 2014-05-16 | 2016-05-06 | Oreal | Composition pour colorer les fibres keratiniques comprenant une base d'oxydation et un coupleur heteroaryle particulier |
| RS60658B1 (sr) * | 2014-06-27 | 2020-09-30 | Celgene Quanticel Research Inc | Inhibitori lizin specifične demetilaze-1 |
| MX391865B (es) * | 2014-07-03 | 2025-03-21 | Celgene Quanticel Res Inc | Inhibidores de demetilasa-1 especifica de lisina. |
-
2015
- 2015-06-29 SG SG11201610975RA patent/SG11201610975RA/en unknown
- 2015-06-29 CN CN201580047448.1A patent/CN106795103B/zh not_active Expired - Fee Related
- 2015-06-29 CA CA2954049A patent/CA2954049A1/en not_active Abandoned
- 2015-06-29 EA EA201790085A patent/EA033698B1/ru not_active IP Right Cessation
- 2015-06-29 AU AU2015284383A patent/AU2015284383B2/en not_active Ceased
- 2015-06-29 EA EA201891526A patent/EA201891526A3/ru unknown
- 2015-06-29 MX MX2020010900A patent/MX395534B/es unknown
- 2015-06-29 PT PT158140384T patent/PT3164380T/pt unknown
- 2015-06-29 ES ES15814038T patent/ES2907676T3/es active Active
- 2015-06-29 MX MX2017000168A patent/MX376207B/es active IP Right Grant
- 2015-06-29 KR KR1020177003162A patent/KR102475498B1/ko active Active
- 2015-06-29 FI FIEP19156976.3T patent/FI3511319T3/fi active
- 2015-06-29 RS RS20230452A patent/RS64423B1/sr unknown
- 2015-06-29 SI SI201531797T patent/SI3164380T1/sl unknown
- 2015-06-29 CN CN201810425583.0A patent/CN108530424B/zh not_active Expired - Fee Related
- 2015-06-29 HU HUE19156976A patent/HUE062558T2/hu unknown
- 2015-06-29 EP EP19156976.3A patent/EP3511319B1/en active Active
- 2015-06-29 LT LTEP19156976.3T patent/LT3511319T/lt unknown
- 2015-06-29 HR HRP20220414TT patent/HRP20220414T1/hr unknown
- 2015-06-29 JP JP2016575768A patent/JP6663866B2/ja not_active Expired - Fee Related
- 2015-06-29 PL PL19156976.3T patent/PL3511319T3/pl unknown
- 2015-06-29 SM SM20220136T patent/SMT202200136T1/it unknown
- 2015-06-29 PL PL15814038T patent/PL3164380T3/pl unknown
- 2015-06-29 WO PCT/US2015/038345 patent/WO2016003917A1/en not_active Ceased
- 2015-06-29 ES ES19156976T patent/ES2948782T3/es active Active
- 2015-06-29 HR HRP20230595TT patent/HRP20230595T1/hr unknown
- 2015-06-29 SM SM20230205T patent/SMT202300205T1/it unknown
- 2015-06-29 DK DK15814038.4T patent/DK3164380T3/da active
- 2015-06-29 BR BR112017000043-1A patent/BR112017000043A2/pt not_active Application Discontinuation
- 2015-06-29 US US15/323,277 patent/US9902719B2/en active Active
- 2015-06-29 HU HUE15814038A patent/HUE058852T2/hu unknown
- 2015-06-29 RS RS20220311A patent/RS63074B1/sr unknown
- 2015-06-29 DK DK19156976.3T patent/DK3511319T3/da active
- 2015-06-29 SI SI201531948T patent/SI3511319T1/sl unknown
- 2015-06-29 PT PT191569763T patent/PT3511319T/pt unknown
- 2015-06-29 LT LTEPPCT/US2015/038345T patent/LT3164380T/lt unknown
- 2015-06-29 EP EP15814038.4A patent/EP3164380B1/en active Active
- 2015-06-29 SG SG10201802501RA patent/SG10201802501RA/en unknown
-
2016
- 2016-12-30 CL CL2016003422A patent/CL2016003422A1/es unknown
-
2017
- 2017-01-01 IL IL249881A patent/IL249881B/en active IP Right Grant
- 2017-01-02 SA SA517380651A patent/SA517380651B1/ar unknown
- 2017-01-23 CO CONC2017/0000549A patent/CO2017000549A2/es unknown
- 2017-02-01 EC ECIEPI20176821A patent/ECSP17006821A/es unknown
-
2018
- 2018-01-10 US US15/867,397 patent/US10100046B2/en active Active
- 2018-09-05 US US16/122,703 patent/US20190002456A1/en not_active Abandoned
-
2019
- 2019-02-21 JP JP2019029856A patent/JP6768857B2/ja not_active Expired - Fee Related
-
2020
- 2020-01-19 IL IL272130A patent/IL272130B/en active IP Right Grant
-
2022
- 2022-04-11 CY CY20221100269T patent/CY1125127T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220414T1 (hr) | Inhibitori lizin specifične demetilaze-1 | |
| RU2475487C2 (ru) | Имидазохинолины с иммуномодулирующими свойствами | |
| JP2017502940A5 (enExample) | ||
| JP2017514830A5 (enExample) | ||
| HRP20201337T1 (hr) | Inhibitori lizin-specifične demetilaze-1 | |
| JP2017521407A5 (enExample) | ||
| HRP20201171T1 (hr) | Derivati izoindolin-1-ona kao modulatori aktivnosti pozitivnog alosternog modulatora kolinergijskog muskarinskog m1 receptora za liječenje alzheimerove bolesti | |
| JP2017525668A5 (enExample) | ||
| JP2017519781A5 (enExample) | ||
| PE20160540A1 (es) | Inhibidores de bromodominios | |
| RU2020110780A (ru) | Ингибитор fgfr и его медицинское применение | |
| RU2011114487A (ru) | Гетероциклические соединения как ингибиторы протеинкиназы | |
| JP2018524390A5 (enExample) | ||
| AR104963A1 (es) | Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak | |
| JP2012512886A5 (enExample) | ||
| AR078157A1 (es) | Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer | |
| HRP20160852T1 (hr) | Biciklični heterociklični spojevi kao inhibitori protein tirozin kinaze | |
| AR090220A1 (es) | Inhibidores de serina/treonina cinasa | |
| ME02648B (me) | Jedinjenje pirazin karboksamida | |
| HRP20210320T1 (hr) | Spojevi heteroarila za liječenje oftalmičkih bolesti | |
| HRP20221454T1 (hr) | Piridinamin-piridonski i pirimidinamin-piridonski spojevi | |
| EA201591675A1 (ru) | Замещенные 7-азабициклы и их применение в качестве модуляторов рецепторов орексина | |
| NZ723502A (en) | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | |
| HRP20120762T1 (hr) | Tetrasupstituirani piridazini kao inhibitori hedgehog puta | |
| HRP20181008T1 (hr) | Terapeutski aktivni pirazolo-pirimidin derivati |